Clinical significance of the immunoglobulin G heavy-chain repertoire in peripheral blood mononuclear cells of adult T-cell leukaemia–lymphoma patients receiving mogamulizumab

Kisato Nosaka,1 Shigeru Kusumoto,2 Nobuaki Nakano,3 Makoto Yoshimitsu,4 Yoshitaka Imaizumi,5 Michihiro Hidaka,7 Hidenori Sasaki,8 Junya Makiyama,9 Eiichi Ohtsuka,10 Tatsuro Jo,11 Masao Ogata,12 Asahi Ito,2 Kentaro Yonekura,13 Hiro Tatetsu,14 Takeharu Kato,6 Toshiro Kawakita,7 Youko Suehiro,4,15 Kenji Ishitsuka,5 Shinsoke Iida,3 Takaji Matsutani,16 Atae Utsunomiya,3 Ryuzo Ueda,17,18 and Takashi Ishida18

1Cancer Center, Kumamoto University Hospital, Kumamoto, 2Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, 3Department of Hematology, Imamura General Hospital, Kagoshima, 4Department of Hematology, National Hospital Organization Kyushu Cancer Centre Hospital, Fukuoka, 5Department of Hematology and Rheumatology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, 6Department of Hematology, Nagasaki University Hospital, Nagasaki, 7Department of Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, 8Division of Medical Oncology, Department of Medicine, Hematology, and Infectious Diseases, Fukuoka University Hospital, Fukuoka, 9Department of Hematology, Sasebo City General Hospital, Sasebo, 10Department of Hematology, Oita Prefectural Hospital, Oita, 11Department of Hematology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, 12Department of Hematology, Oita University Hospital, Oita, 13Department of Dermatology, Imamura General Hospital, Kagoshima, 14Department of Hematology, Kumamoto

Summary

‘Monitoring of immune responses following mogamulizumab-containing treatment in patients with adult T-cell leukaemia–lymphoma (ATL)’ (MIMOGA) is a multicentre prospective clinical study (UMIN000008696). In the MIMOGA study, we found that a lower percentage of CD2+CD19+ B cells in peripheral blood mononuclear cells (PBMC) was a significant unfavourable prognostic factor for overall survival (OS). Accordingly, we then analysed the immunoglobulin G (IgG) heavy-chain repertoire in PBMC by high-throughput sequencing. Of the 101 patients enrolled in the MIMOGA study, for 81 a sufficient amount of PBMC RNA was available for repertoire sequencing analysis. Peripheral IgG B cells in patients with ATL had a restricted repertoire relative to those in healthy individuals. There was a significant positive correlation between the Shannon–Weaver diversity index (SWDI) for the IgG repertoire and proportions of B cells in the PBMC of the patients. Multivariate analysis identified two variables significantly affecting OS: a higher serum soluble interleukin-2 receptor level, and a lower SWDI for the IgG repertoire [hazard ratio, 2.124; 95% confidence interval, 1.114–4.049; n = 44]. The present study documents the importance of humoral immune responses in patients receiving mogamulizumab-containing treatment. Further investigation of strategies to enhance humoral immune responses in patients with ATL is warranted.

Keywords: adult T-cell leukaemia–lymphoma, mogamulizumab, immunoglobulin G B-cell diversity.
University Hospital, Kumamoto,  
15Department of Cell, Therapy National  
Hospital Organization Kyushu Cancer  
Centre Hospital, Fukuoka,  
16Osaka laboratory, Repertoire Genesis  
Incorporation, Ibaraki, Osaka,  
17Department of Tumor Immunology, Aichi  
Medical University School of Medicine,  
Nagakute, and  
18Department of  
Immunology, Nagoya University Graduate  
School of Medicine, Nagoya, Japan

Received 3 August 2021; accepted for 
publication 29 September 2021  
Correspondence: Takashi Ishida, Department  
of Immunology, Nagoya University Graduate  
School of Medicine, 65 Tsurumai-cho,  
Showa-ku, Nagoya, Aichi 466-8560, Japan.  
E-mail: itakashi@med.nagoya-u.ac.jp

Introduction

Adult T-cell leukaemia–lymphoma (ATL) is a peripheral T-cell neoplasm caused by human T-cell lymphotropic virus type 1 (HTLV-1). It has a grave prognosis, partially due to patients’ severely immunocompromised state.1–4 Because CC chemokine receptor 4 (CCR4) is expressed on tumour cells from most patients with ATL,5,6 a therapeutic anti-CCR4 monoclonal antibody, mogamulizumab, has been developed to specifically target this molecule.7–9 Although mogamulizumab treatment offers a clinical benefit to patients with ATL, some patients are initially refractory to the antibody, or acquire resistance on treatment.10–16 In addition, many patients still suffer from lethal opportunistic infections.3,4,17 In this context, we planned and conducted the ‘Monitoring of immune responses following mogamulizumab-containing treatment in patients with ATL’ (MIMOGA), a multicentre prospective observational study (UMIN000008696), in order to establish the most effective and safe treatment strategy using mogamulizumab in patients with ATL.18 Consequently, we have found that having a lower percentage of CD20+/CD19+ B cells within the lymphocyte population in peripheral blood mononuclear cells (PBMC) were an independent and significant unfavourable prognostic factor for overall survival (OS) in patients with ATL.18 This finding highlighted the potential importance of humoral immune responses during treatment for ATL, and prompted us to investigate the B-cell immune system in detail by analysing the B-cell repertoire in patients with ATL.18 Collectively, in the present study we focused on IgG memory B cells.25,26 One important reason for this is that secreted IgG is the most predominant isotype found in the human body, and another reason is that IgG is not expressed by naïve B cells; thus we can analyse memory B cells clearly separate from naïve B cells. Collectively, in the present study, we analysed the IgG heavy-chain repertoire of PBMC in patients with ATL and explored its clinical and immunological significance, especially focussing on the degree of diversity.

Patients and methods

Patients and study design

The present study was affiliated with the MIMOGA study. For patients enrolled in this trial, three additional inclusion criteria were used: (i) those patients who provided written informed consent for genomic analysis at enrolment in the MIMOGA study, according to the principles of the Declaration of Helsinki, (ii) those patients in whom both the quality and quantity of total RNA extracted from their PBMC before mogamulizumab treatment reached the level required for IgG heavy-chain repertoire analysis, and (iii) those patients in whom more than 200 in-frame productive IgG sequence reads were
obtained from their RNA. This third criterion was intended to minimize the possibility of including data with sequencing errors or insufficient RNA. Of the 101 patients who received mogamulizumab-containing treatment in the MIMOGA study, 81 were eligible according to these criteria and they were all enrolled in the present substudy (Fig 1). The clinical information and immunological data of these patients, recorded in the MIMOGA study, were also available to the present study.18

Unbiased amplification and high-throughput sequencing of IgG heavy-chain genes

The details are available in Data S1.27

Data analyses

Each sequence read was analysed by bioinformatics software created by Repertoire Genesis Incorporation, Osaka Laboratory (Ibaraki, Japan), and the use of IgG heavy-chain variable (IGHV) segments, diversity (IGHD), joining (IGHJ), and constant (IGHC) region segments, and CDR3 sequences were determined as previously reported.27,28 Briefly, the identification of V, D, J, and C regions was determined by the sequence with the highest identity to reference sequence datasets available from the international ImMunoGeneTics (IMGT) database (http://www.imgt.org). Unproductive reads (out-of-frame reads) were excluded and only the productive reads (in-frame reads) were used in further analyses. The identical V, D, J, and deduced amino acid sequences of CDR3 were defined as a unique sequence read. The unique reads with in-frame CDR3 nucleotide sequences were used for calculation of diversity indices for the IgG heavy-chain repertoire. The details are available in Data S1.

Repertoire diversity

The Shannon–Weaver diversity index (SWDI),29,30 in which large numbers denote higher diversity, was calculated using R (R-3.4.3) (http://www.R-project.org) and its package vegan. The data analyses including SWDI were performed by Repertoire Genesis Incorporation.

Statistical analysis

Survival estimates were calculated using the Kaplan–Meier method. OS was measured from the day of the first dose of mogamulizumab to death resulting from any cause. The survival estimate was calculated with all transplanted patients (n = 10) censoring at the day of allogeneic haematopoietic stem cell transplantation, in the same manner as in a previous study.17 Correlations between two variables were assessed using Spearman rank correlation coefficients (Rs). Differences between the two groups were examined with a Mann–Whitney U-test or Fisher’s exact test. Clinically meaningful cut-off values of the SWDI for the IgG heavy-chain repertoire in PBMC of patients with ATL have not been determined thus far. Hence, we attempted to divide such patients into two groups according to this parameter. The cut-off values of SWDI for the IgG heavy-chain repertoire were tested at six different points between the 30th and 70th percentiles (30th, 38th, 46th, 54th, 62nd, and 70th percentiles). Subsequently, univariate analysis for survival was performed using a Cox proportional hazards regression model according to the SWDI for the IgG heavy-chain repertoire in PBMC at each of the six cut-off points. In the present study, the cut-off point yielding the minimum P value was selected as the most meaningful cut-off value.31 The cut-off value of the percentage of CD2 -CD19 B cells within lymphocytes in PBMC was set at 0.15% according to our previous study.18 Univariate and multivariate analyses using Cox proportional hazards regression models was applied to evaluate variables potentially affecting OS. In this study, P < 0.05 (two-sided) was considered significant. The details are available in Data S1.

Results

Patients’ characteristics according to SWDI for the IgG heavy-chain repertoire in PBMC

The SWDI for the IgG heavy-chain repertoire in PBMC of 81 patients enrolled in the present study was 4.78, 5.25, and
K. Nosaka et al.

1:02–10:13 (mean, median, and range), whereas these values were 8:46, 8:50, and 7:10–9:61 in healthy controls previously analysed in the same manner.27 Thus, the IgG repertoire of peripheral B cells from patients with ATL was significantly less diverse than in healthy individuals (P < 0:001). A three-dimensional graphical representation of the IgG heavy-chain repertoire of an ATL patient before mogamulizumab-containing treatment with the highest SWDI (SWDI = 10:13) in the approximately 30th (5:73), 50th (5:25), and 70th (3:53) percentiles in descending order, as well as in the lowest (1:02), is shown in Figs 2A–E, respectively. In addition, pie charts of the IgG heavy-chain repertoire for all 81 patients are shown in Figure S1. In the present study, the cut-off value of SWDI for the IgG heavy-chain repertoire in PBMC was set at 5:38 (Table S1). The clinical characteristics according to the SWDI for the IgG heavy-chain repertoire of such patients are summarized in Table I. The median ages were 69 (range, 41–86) and 68 years (range, 41–83) in patients with a lower and higher SWDI, respectively (not significantly different). There were also no significant differences between patients with a lower or higher SWDI regarding previous systemic chemotherapy (yes or no), sex (female or male), Eastern Cooperative Oncology Group performance status [ECOG PS; 0 (n = 23), 1 (n = 35), or 2 (n = 14), 3 (n = 7), 4 (n = 2)], serum soluble interleukin-2 receptor (sIL–2R; ≤20 000 or >20 000 U/ml), serum adjusted calcium (Ca; ≤11:0 or >11:0 mg/dl), or serum albumin (Alb; <3:5 or ≥3:5 g/dl). There were also no significant differences between patients with a lower or higher SWDI for clinical subtype (chronic [n = 11], smouldering [n = 2], or acute [n = 52], or lymphoma [n = 16]; Table I). In this context, there were also no significant differences in the SWDI for the IgG repertoire between patients with acute (4:84 [mean], 5:31 [median]) and lymphoma (4:56, 4:34) subtypes (P = 0:613). The HTLV-1 provirus load (PVL) in PBMC tended to be higher in patients with a lower SWDI compared to those with a higher SWDI (P = 0:090; Table I).

Immunological characteristics according to the SWDI for the IgG heavy-chain repertoire in PBMC of patients with ATL are summarized in Table II. The percentage of CD2+ CD19+ B cells was significantly higher in patients with a higher SWDI (P = 0:022). The percentage of CD11c+ monocytes within the monocyte population in PBMC was also significantly higher in patients with a higher SWDI compared to those with a lower SWDI (P = 0:029), but there were no differences in the percentages of CD3+CD8+ T cells or CD16+CD56+ natural killer (NK) cells between patients with a higher or lower SWDI (Table II). There were also no significant differences between percentages of CD4+, CD4+FOX-P3lowCD45RA−, CD4+FOX-P3highCD45RA−, or CD4+FOX-P3lowCD45RA− T cells in patients with a higher or lower SWDI. Finally, there were also no differences for FOX-P3lowCD45RA−, FOX-P3highCD45RA−, or FOX-P3lowCD45RA− T cells within CD4+ lymphocytes in patients with a higher or lower SWDI (Table II).

Correlations between the SWDI for the IgG heavy-chain repertoire in PBMC and clinical or immunological parameters of ATL patients before starting mogamulizumab

No significant correlation was noted between the SWDI for the IgG heavy-chain repertoire in PBMC and the HTLV-1 PVL (R = −0:124, P = 0:269), or serum sIL–2R levels (R = 0:057, P = 0:611). However, a weak but significant positive correlation between the SWDI for the IgG repertoire and percentages of CD2+ CD19+ B cells was seen (R = 0:291, P = 0:008). No correlations were seen between the SWDI and percentages of CD3+CD8+ T (R = −0:078, P = 0:489), or CD16+CD56+ NK (R = 0:075, P = 0:508) cells within the lymphocyte population, or CD11c+ monocytes within the monocyte population (R = 0:182, P = 0:105). There were also no significant correlations between the SWDI for the IgG repertoire and percentages of CD4+ (R = −0:125, P = 0:267), CD4+FOX-P3lowCD45RA− (R = 0:058, P = 0:608), CD4+FOX-P3highCD45RA− (R = 0:043, P = 0:705), and CD4+FOX-P3lowCD45RA− (R = 0:061, P = 0:587) T cells. Finally, there were also no significant correlations between the SWDI and FOXP3low–C–D45RA− (R = 0:070, P = 0:534), FOXP3high–CD45RA− (R = 0:045, P = 0:689), and FOXP3low–CD45RA− (R = 0:084, P = 0:455) T cells within the CD4+ lymphocyte subset.

Overall survival of patients according to the SWDI for the IgG heavy-chain repertoire in PBMC

In the entire patient cohort of the present study, the median OS was 16:0 months [95% confidence interval (CI), 9:9–22:1, Fig 3A)]. The SWDI for the IgG heavy-chain repertoire tended to be associated with OS [lower compared with higher; hazard ratio (HR), 1:608; 95% CI, 0:876–2:951; Fig 3B]. However, the SWDI for the IgG heavy-chain repertoire together with the percentage of CD2+ CD19+ B cells within lymphocytes was significantly associated with OS [a lower SWDI and a lower percentage of CD2+ CD19+ B cells within lymphocytes (≤0:15%) compared with the other; HR, 2:892; 95% CI, 1:347–6:206; Fig 3C].

Univariate and multivariate analyses for OS including the SWDI for the IgG heavy-chain repertoire in PBMC

Univariate analyses demonstrated that sex (male vs female; HR, 1:017; 95% CI, 0:552–1:876), and age (>70 vs ≤70 years; HR, 1:109; 95% CI, 0:603–2:039) were not associated with OS. Univariate analyses also indicated that clinical subtype (acute or lymphoma versus chronic or smouldering; HR, 2:997; 95% CI, 1:065–8:437), ECOG PS (2, 3 or 4, relative to 0 or 1; HR, 1:994; 95% CI, 1:066–3:729), and serum sIL–2R level (>20 000 vs ≤20 000 U/ml; HR, 5:352; 95% CI, 2:649–10:812) were significantly associated with OS.

Subsequently, multivariate analysis of OS in the 81 patients was performed using the following six variables: sex,
Fig 2. Three-dimensional graphical representation of the immunoglobulin G (IgG) heavy-chain repertoire in peripheral blood mononuclear cells (PBMC). The x-axis (width) and y-axis (depth) indicate V and J genes, respectively. The z-axis (height) represents frequencies of V–J combinations. The total of the frequencies is 100%. The IgG heavy-chain repertoire in PBMC in adult T-cell leukaemia–lymphoma (ATL) patients with a Shannon–Weaver diversity index (SWDI) that is in the highest (SWDI = 10.13; A), approximately 30th (5.73; B), approximately 50th (5.25; C), and approximately 70th (3.53; D) percentiles, in descending order, and that in the lowest percentile (1.02; E) are shown. [Colour figure can be viewed at wileyonlinelibrary.com]
Table I. Clinical characteristics of ATL patients according to SWDI for the IgG heavy-chain repertoire in PBMC.

| Characteristics                      | <5.38 | ≥5.38 | P value |
|--------------------------------------|-------|-------|---------|
| Number (%)                           | 44 (54) | 37 (46) | 0.958   |
| Age (year)                           |       |       |         |
| Mean                                 | 68    | 69    |         |
| Median                               | 69    | 68    |         |
| Range                                | 41–86 | 41–83 |         |
| Previous systemic chemotherapy       |       |       | 0.579   |
| Yes                                  | 10 (23) | 6 (16) |         |
| No                                   | 34 (77) | 31 (84) |         |
| Sex                                  |       |       | 0.252   |
| Female                               | 30 (68) | 20 (54) |         |
| Male                                 | 14 (32) | 17 (46) |         |
| Clinical subtype                     |       |       | 1.000   |
| Chronic, smouldering                 | 7 (16) | 6 (16) |         |
| Acute, lymphoma                      | 37 (84) | 31 (84) |         |
| ECOG PS                              |       |       | 0.323   |
| 0, 1                                 | 29 (66) | 29 (78) |         |
| 2, 3, 4                              | 15 (34) | 8 (22) |         |
| Serum sIL-2R (U/ml)                  |       |       | 0.278   |
| <20 000                              | 37 (84) | 27 (73) |         |
| ≥20 000                              | 7 (16) | 10 (27) |         |
| Serum Ca (mg/dl)*                    |       |       | 0.655   |
| ≤11.0                                | 41 (95) | 33 (92) |         |
| >11.0                                | 2 (5) | 3 (8) |         |
| Serum albumin (g/dl)*                |       |       | 0.643   |
| ≥3.5                                 | 26 (79) | 24 (67) |         |
| <3.5                                 | 17 (21) | 12 (33) |         |
| HTLV-1 PVL (copies/1 000 PBMC)       |       |       | 0.090   |
| Mean                                 | 571.6 | 379.2 |         |
| Median                               | 458.6 | 219.9 |         |
| Range                                | 0.8–3 093.7 | 0.5–1 919.5 | |

Alb, albumin; ATL, adult T-cell leukaemia—lymphoma; Ca, calcium; ECOG, Eastern Cooperative Oncology Group; IgG, immunoglobulin G; PBMC, peripheral blood mononuclear cells; PS, performance status; sIL-2R, soluble interleukin-2 receptor; SWDI, Shannon–Weaver diversity index.

*The data of two patients were unknown.
†When serum Alb level was less than 4.0 g/dl, serum Ca was adjusted by the concentration of serum Alb as follows: adjusted Ca level (mg/dl) = measured Ca level (mg/dl) + [4-albumin level (g/dl)]. HTLV-1, human T cell lymphotropic virus type 1; PVL, provirus load.

Table II. Immunological characteristics of ATL patients according to SWDI for the IgG heavy-chain repertoire in PBMC.

| Characteristics                      | <5.38 | ≥5.38 | P value |
|--------------------------------------|-------|-------|---------|
| Number (%)                           | 44 (54) | 37 (46) | 0.022   |
| CD2+CD19+ cells (%)*                 |       |       |         |
| Mean                                 | 1.23 | 4.20 |         |
| Median                               | 0.49 | 1.25 |         |
| Range                                | 0.00–8.17 | 0.03–32.91 | |
| CD3+CD8+ cells (%)*                  |       |       | 0.857   |
| Mean                                 | 14.70 | 12.78 |         |
| Median                               | 8.94 | 9.65 |         |
| Range                                | 0.10–71.73 | 0.60–52.33 | |
| CD16+CD56+ cells (%)†                |       |       | 0.197   |
| Mean                                 | 7.24 | 10.52 |         |
| Median                               | 3.83 | 6.64 |         |
| Range                                | 0.07–31.57 | 0.18–39.42 | |
| CD11c monocytes (%)†                 |       |       | 0.029   |
| Mean                                 | 50.91 | 65.42 |         |
| Median                               | 51.62 | 78.60 |         |
| Range                                | 0.50–97.18 | 0.34–95.76 | |
| CD4+ cells (%)*                      |       |       | 0.308   |
| Mean                                 | 64.90 | 59.55 |         |
| Median                               | 68.86 | 62.67 |         |
| Range                                | 11.16–98.14 | 14.60–97.86 | |
| CD4+FOXP3lowCD45RA* cells (%)*       |       |       | 0.271   |
| Mean                                 | 0.21 | 0.34 |         |
| Median                               | 0.07 | 0.16 |         |
| Range                                | 0.00–1.27 | 0.00–4.71 | |
| FOXP3highCD45RA+ cells (%)†          |       |       | 0.135   |
| Mean                                 | 0.34 | 0.62 |         |
| Median                               | 0.14 | 0.26 |         |
| Range                                | 0.00–1.50 | 0.00–7.64 | |
| CD4+FOXP3highCD45RA+ cells (%)*      |       |       | 0.712   |
| Mean                                 | 19.08 | 15.41 |         |
| Median                               | 2.16 | 2.66 |         |
| Range                                | 0.00–87.26 | 0.00–83.09 | |
| FOXP3highCD45RA+ cells (%)†          |       |       | 0.649   |
| Mean                                 | 24.63 | 21.11 |         |
| Median                               | 4.84 | 6.17 |         |
| Range                                | 0.00–90.91 | 0.00–88.80 | |
| CD4+FOXP3lowCD45RA+ cells (%)*       |       |       | 0.726   |
| Mean                                 | 16.75 | 11.06 |         |
| Median                               | 3.19 | 4.01 |         |
| Range                                | 0.21–88.41 | 0.17–61.12 | |

ATL, adult T-cell leukaemia—lymphoma; IgG, immunoglobulin G; PBMC, peripheral blood mononuclear cells; SWDI, Shannon–Weaver diversity index.

*The percentage among whole lymphocytes in PBMC.
†The percentage among whole monocytes in PBMC.
‡The percentage among CD4+ lymphocytes in PBMC.
lymphocytes (≤ 18% than other patients (median OS, 7 months); Table III). However, the HTLV-1 PVL in PBMC tended to be higher in patients with a lower SWDI for the IgG repertoire, indicating that ATL disease status seems not to be directly associated with the degree of IgG B-cell diversity in patients with ATL, partially because the tumour cells were significantly less diverse than those in healthy individuals, is consistent with the fact that patients with ATL are severely immunocompromised. In this context, it has been generally accepted that cellular immune responses are attenuated in patients with ATL, partially because the tumour cells from a subset of patients actually function as regulatory T (Treg) cells. Furthermore, the present finding of a shrunken IgG B-cell pool indicates that there is only a limited variety of memory B cells poised to respond to the corresponding pathogen antigens, which would lead to attenuated humoral immune responses.

The present study did not identify the definitive clinical factors correlating with higher or lower IgG B-cell diversity in these ATL patients. Such clinical factors included serum sIL-2R levels, which reflect the ATL tumour burden. In this context, no significant correlation between the SWDI for the IgG heavy-chain repertoire and serum sIL-2R level was observed, indicating that ATL disease status seems not to be directly associated with the degree of IgG B-cell diversity in PBMC. In comparison, the HTLV-1 PVL in PBMC tended to be higher in patients with a lower SWDI for the IgG repertoire relative to those with a higher SWDI, although this difference did not achieve statistical significance. This may suggest that the HTLV-1-infected cells inhibited the generation and diversification of IgG B cells.

Table III. Multivariate analysis including SWDI for the IgG heavy-chain repertoire in PBMC for OS in patients with ATL.

| Variables                  | Hazard ratio (95% CI) | P value |
|----------------------------|-----------------------|---------|
| Sex                        |                       |         |
| Female                     | 1.000                 | Reference |
| Male                       | 1.175 (0.612–2.255)   | 0.628   |
| Age, years                 |                       |         |
| ≤70                        | 1.000                 | Reference |
| >70                        | 1.154 (0.605–2.200)   | 0.663   |
| Clinical subtype           |                       |         |
| Chronic                    | 1.000                 | Reference |
| Smouldering                | 2.425 (0.801–7.343)   | 0.117   |
| Acute, lymphoma            |                       |         |
| ECOG PS                    |                       |         |
| 0, 1                       | 1.000                 | Reference |
| 2, 3, 4                    | 1.231 (0.624–2.428)   | 0.548   |
| sIL-2R (U/ml)              |                       |         |
| ≤20 000                    | 1.000                 | Reference |
| >20 000                    | 5.036 (2.377–10.669)  | <0.001  |
| SWDI for IgG heavy-chain repertoire in PBMC | |         |
| ≥5–38                      | 1.000                 | Reference |
| <5–38                      | 2.124 (1.114–4.049)   | 0.022   |

ATL, adult T-cell leukaemia–lymphoma; IgG, immunoglobulin G; SWDI, Shannon–Weaver diversity index; PBMC, peripheral blood mononuclear cells; CI, confidence interval.

Discussion

Here, we have analysed the IgG heavy-chain repertoire in PBMC of patients who were prospectively enrolled in the MIMOGA study, and received mogamulizumab-containing treatment. We explored the clinical and immunological significance of IgG B-cell diversity in patients with ATL. The present finding, that peripheral IgG B cells in these patients were significantly less diverse than those in healthy individuals, is consistent with the fact that patients with ATL are severely immunocompromised. In this context, it has been generally accepted that cellular immune responses are attenuated in patients with ATL, partially because the tumour cells from a subset of patients actually function as regulatory T (Treg) cells. Furthermore, the present finding of a shrunken IgG B-cell pool indicates that there is only a limited variety of memory B cells poised to respond to the corresponding pathogen antigens, which would lead to attenuated humoral immune responses.

The present study did not identify the definitive clinical factors correlating with higher or lower IgG B-cell diversity in these ATL patients. Such clinical factors included serum sIL-2R levels, which reflect the ATL tumour burden. In this context, no significant correlation between the SWDI for the IgG heavy-chain repertoire and serum sIL-2R level was observed, indicating that ATL disease status seems not to be directly associated with the degree of IgG B-cell diversity in PBMC. In comparison, the HTLV-1 PVL in PBMC tended to be higher in patients with a lower SWDI for the IgG repertoire relative to those with a higher SWDI, although this difference did not achieve statistical significance. This may suggest that the HTLV-1-infected cells inhibited the generation and diversification of IgG B cells.
Table IV. Multivariate analysis including SWDI for the IgG heavy-chain repertoire in PBMC and the percentage of CD2+CD19+ B cells for OS in patients with ATL.

| Variables                      | Hazard ratio (95% CI) | P value |
|--------------------------------|-----------------------|---------|
| Sex                            |                       |         |
| Female                         | 1.000                 | Reference |
| Male                           | 0.971 (0.521–1.809)   | 0.927   |
| Age, years                     |                       |         |
| ≤70                            | 1.000                 | Reference |
| >70                            | 1.121 (0.599–2.099)   | 0.721   |
| Clinical subtype               |                       |         |
| Chronic, smouldering           | 1.000                 | Reference |
| Acute, lymphoma                | 1.943 (0.647–5.838)   | 0.236   |
| ECOG PS                        |                       |         |
| 2, 3, 4                        | 1.234 (0.638–2.389)   | 0.532   |
| ≤20 000                        | 4.907 (2.337–10.303)  | <0.001  |
| >20 000                        | 5.32                 |         |
| SWDI for IgG heavy-chain repertoire and CD2+CD19+ cells (%)† |                       |         |
| ≥5–38 or ≤0.15                 | 1.000                 | Reference |
| <5–38 & ≤0.15                  | 2.909 (1.322–6.398)   | 0.008   |

ATL, adult T-cell leukaemia–lymphoma; CI, confidence interval; IgG, immunoglobulin G; PBMC, peripheral blood mononuclear cells; SWDI, Shannon–Weaver diversity index.

*OS, overall survival. The patients were censored at the day of allogeneic haematopoietic stem cell transplantation.

†The percentage among whole lymphocytes in PBMC.

Regarding immunological parameters, the proportion of CD2+CD19+ B cells was significantly higher in patients with a higher SWDI for the IgG repertoire in PBMC, and a significant positive correlation between these two parameters was also observed. These findings possibly indicate that the more B cells, including IgG B cells, are present in the body, the more they can diversify. The proportion of CD11c+ monocytes within the monocyte population also tended to be higher in patients with a higher SWDI, although a significant correlation between these two parameters was not observed. The precise relationship between CD11c+ monocytes and IgG B-cell diversity has not yet been elucidated, and thus further investigation regarding this matter is warranted. With respect to CD4+ T cells, including cells with an effector Treg phenotype, there was no association with IgG B-cell diversity. We have previously reported that the IgM heavy-chain repertoire in PBMC became less diverse at the time of occurrence of skin-related adverse events related to mogamulizumab treatment, which results in the depletion of cells with an effector Treg phenotype. The relationship between Treg phenotype and B-cell diversity is not fully clarified as yet, thus also warranting further investigation.

The present study documented that the lower IgG B-cell diversity in PBMC, especially together with lower percentages of CD2+CD19+ B cells, was an independent unfavourable prognostic factor in patients with ATL receiving mogamulizumab-containing treatment. This may be because only a small set of memory B cells is poised to respond to the corresponding pathogen antigens in patients with a lower IgG B-cell diversity. When the patients’ B-cell counts are also low, this limited variety of memory B cells inevitably carries more severe implications. Accordingly, patients with a lower IgG B-cell diversity would be expected to show weaker humoral immune responses, contributing to a poorer prognosis. From this point of view, appropriate intravenous polyclonal immunoglobulin therapy may be effective for treating opportunistic infections in patients with ATL receiving mogamulizumab-containing treatment.

Although the present investigation offers significant observations regarding IgG B-cell diversity for clinical outcomes in ATL patients undergoing mogamulizumab-containing treatment, several limitations must be recognized. First, the study included both previously untreated patients and those treated with systemic chemotherapy. Second, some patients received mogamulizumab monotherapy, whereas others received different combination therapies. These variables might both affect the conclusions of the present study. Finally, the relationship and difference in IgG B-cell diversity in different organs, such as lymphoid tissues or bone marrow, and not only in PBMC as studied here, also requires analysis in humans.

In conclusion, the present study demonstrated that peripheral IgG B cells in patients with ATL were less diverse than in healthy individuals. In addition, the study demonstrated that the lower IgG B-cell diversity in PBMC, especially together with a lower percentage of CD2+CD19+ B cells, was an independent unfavourable prognostic factor. The present observations highlight the importance of humoral immune responses for the clinical outcomes of ATL patients receiving mogamulizumab-containing treatment. Further investigation of strategies to enhance humoral immune responses, including the diversification of memory B cells in patients with ATL, is highly warranted.

Acknowledgements

We thank all nurses and clinical research coordinators who were involved in this study, for their patient care and schedule management. We also thank the Japan Institute of Statistical Technology (Tokyo, Japan) for their critical review of the statistical analyses, and for providing a certificate attesting the validity of the statistical methods used for the data analyses in the present manuscript. We are grateful to Mr. Hiroshi Iwata (SRL Medisearch Inc., Tokyo, Japan) for his support in scheduling samples from patients, and for sample preservation. We are also grateful to Dr. Satoshi Shinohara (Repertoire Genesis Incorporation) for his fruitful discussion with us. We also thank Professor Hiroyoshi Nishikawa (Nagoya University Graduate School of Medicine) for his helpful advice.
Funding information

This work was supported by a grant-in-aid for scientific research (C) (21K08374 to KN), and by grants-in-aid from the Japan Agency for Medical Research and Development (No. 20ae0101074h0001 and 21ae0101074h0001 to RU, and No. 20cm0106301h0005 and 21cm0106301h0005 to TI).

Author contribution

Conception and design: KN, RU, TI. Acquisition and analysis of data: KN, SK, NN, IC, MY, YI, MH, HS, JM, EO, TJ, MO, AI, KY, HT, TaK, ToK, YS, KS, SI, TM, AU, TI. Data interpretation: KN, RU, TI. Manuscript writing and final approval of manuscript: all authors.

Conflicts of interest

KN has received consultancy fees, research funding and honoraria from Kyowa Kirin, research funding from Chugai Pharmaceutical, and honoraria from Celgene, Eisai, Meiji Seika Pharma, Janssen Pharmaceutical and Bristol Myers Squibb. SK has received consultancy fees, research funding and honoraria from Chugai Pharmaceutical, research funding and honoraria from Kyowa Kirin, Daichi Sankyo, Takeda Pharmaceutical, Janssen Pharmaceutical and honoraria from Otsuka Pharmaceutical and Eisai. NN has received consultancy fees from JIMRO and honoraria from Novartis, Takeda Pharmaceutical, Chugai Pharmaceutical, Celgene, Otsuka Pharmaceutical, Nippon Shinyaku, Kyowa Kirin and Asahi Kasei Pharma. IC has received honoraria from Kyowa Kirin, Celgene, Eisai, Bristol Myers Squibb and Sanofi. MH has received research funding from Chugai Pharmaceutical and honoraria from Nippon Shinyaku and Symbio Pharma. KY has received honoraria from Abbvie, Amgen, Celgene, Daichi Sankyo, Eli Lilly Japan, Janssen Pharmaceutical, Kaken Pharmaceutical, Kyowa Kirin, Maruho, Minophagen Pharmaceutical, Novartis, Sanofi, Taiho Pharmaceutical, Torii Pharmaceutical, UCB Japan, Eisai, Sun Pharma Japan. HT has received honoraria from Ono Pharmaceutical, Chugai Pharmaceutical, Eisai, Novartis International and patients, and royalties from Mesoblast. YS has received research funding and honoraria from Kyowa Kirin and honoraria from Celgene and Bristol Myers Squibb. KS has received research funding and honoraria from Kyowa Kirin. SI has received research funding and honoraria from Kyowa Kirin. AI has received research funding from Biogen, Genentech, Janssen Pharmaceutical, and Ono Pharmaceutical, and honoraria from信州大学和千代田制药。TaK, ToK, and TI have no conflicts of interest to disclose.

Supporting Information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Data S1. Supplementary Methods.

Fig S1. Pie charts of the immunoglobulin G (IgG) heavy-chain repertoire in peripheral blood mononuclear cells (PBMC). Pie charts showing the IgG heavy-chain repertoires in PBMC in 81 adult T-cell leukaemia–lymphoma (ATL) patients. The unique reads with in-frame CDR3 nucleotide sequences whose frequencies are 0.1% or higher are shown by individual colours, and those that are less than 0.1% are shown in grayscale. The pie charts are presented in ascending order of Shannon–Weaver diversity index (SWDI) for the IgG heavy-chain repertoire, from upper left to lower right. The SWDIs are indicated to the upper left of the pie charts in the left, middle, and right columns. Pie charts labelled A, B, C, D, E at their upper right correspond to A, B, C, D, E, respectively, in the three-dimensional graphical representation in Fig. 2. The upper 44 cases are those of the lower SWDI group (<5.38), and the lower 37 cases are included in the higher SWDI group (>5.38).

Table S1. Univariate Cox proportional hazard analysis for overall survival (OS) according to the Shannon–Weaver diversity index (SWDI) for the immunoglobulin G (IgG) heavy-chain repertoire in peripheral blood mononuclear cells (PBMC).

References

1. Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T-cell leukaemia: clinical and hematologic features of 16 cases. Blood. 1977;50:481–92.
2. Shimoyma M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984–1987). Br J Haematol. 1991;79:428–37.
3. Ishitoku K, Tamura K. Human T-cell leukaemia virus type 1 and adult T-cell leukaemia-lymphoma. Lancet Oncol. 2014;15:e517–e526.
4. Matsuoka K, Jeang KT. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer. 2007;7:270–80.
5. Yoshie O, Fujisawa R, Nakayama T, Harasawa H, Tago H, Izawa D, et al. Frequent expression of CCR4 in adult T-cell leukaemia and human T-cell leukemia virus type 1-transformed T cells. Blood. 2002;99:1505–11.
6. Ishida T, Utsunomiya A, Iida S, Inagaki H, Takatsuki Y, Kusumoto S, et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res. 2003;9:3625–34.
7. Ishida T, Iida S, Akatsuka Y, Ishii T, Miyazaki M, Komatsu H, et al. The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-cell leukemia/lymphoma. Clin Cancer Res. 2004;10:7529–39.
8. Ito A, Ishida T, Utsunomiya A, Sato F, Mori F, Yano H, et al. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against...
primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo. J Immunol. 2009;183:4782–91.
9. Ishii T, Ishida T, Utsunomiya A, Inagaki A, Yano H, Komatsu H, et al. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. Clin Cancer Res. 2010;16:1520–31.
10. Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30:837–42.
11. Ishida T, Jo T, Takemoto S, Suzushima H, Uozumi K, Yamamoto K, et al. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukemia-lymphoma: a randomized phase II study. Br J Haematol. 2015;169:672–82.
12. Ishida T, Utsunomiya A, Jo T, Yamamoto K, Kato K, Yoshida S, et al. Mogamulizumab for relapsed adult T-cell leukemia-lymphoma: Updated follow-up analysis of phase I and II studies. Cancer Sci. 2017;108:2022–9.
13. Ishida T, Jo T, Takemoto S, Suzushima H, Suehiro Y, Choi I, et al. Follow-up of a randomised phase II study of chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukemia-lymphoma: impact on allelogeneic haematopoietic stem cell transplantation. Br J Haematol. 2019;184:479–87.
14. Sakamoto Y, Ishida T, Masaki A, Murase T, Yonekura K, Tashiro Y, et al. CCR4 mutations associated with superior outcome of adult T-cell leukemia/lymphoma under mogamulizumab treatment. Blood. 2018;132:758–61.
15. Sakamoto Y, Ishida T, Masaki A, Takeshita M, Iwasaki H, Yonekura K, et al. Clinical significance of CD28 gene-related activating alterations in adult T-cell leukemia/lymphoma. Br J Haematol. 2021;192:281–91.
16. Sakamoto Y, Ishida T, Masaki A, Murase T, Takeshita M, Muto R, et al. Clinical significance of TP53 mutations in adult T-cell leukemia-lymphoma. Br J Haematol. 2021; https://doi.org/10.1111/bjh.17749. [Online ahead of print].
17. Ishida T, Ueda R. Immunopathogenesis of lymphoma: focus on CCR4. Cancer Sci. 2011;102:44–50.
18. Yonekura K, Kusumoto S, Choi I, Nakano N, Ito A, Suehiro Y, et al. Mogamulizumab for adult T-cell leukemia-lymphoma: a multicenter prospective observational study. Blood Adv. 2020;4:5133–45.
19. Rajewsky K. Clonal selection and learning in the antibody system. Nature. 1996;381:751–8.
20. Klein U, Dalla-Favera R. Germinal centres: role in B-cell physiology and malignancy. Nat Rev Immunol. 2008;8:32–33.
21. Kataoka T, Miyata T, Honjo T. Repetitive sequences in class switch recombination regions of immunoglobulin heavy chain genes. Cell. 1981;23:357–68.
22. Klein U, Rajewsky K, K üppers R. Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J Exp Med. 1998;188:1679–89.